Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @DrGlenWeiss et al. OncoTargets and Therapy https://t.co/Ipxd3VVyk2 #PrecisionMedicine https://t.c
Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @DrGlenWeiss et al. OncoTargets and Therapy https://t.co/Ipxd3VVyk2 #PrecisionMedicine
RT @DrGlenWeiss: @VPrasadMDMPH 5 yrs after reporting that a heavily promoted NGS service was reporting drug target associations as rx recs…
RT @DrGlenWeiss: @VPrasadMDMPH 5 yrs after reporting that a heavily promoted NGS service was reporting drug target associations as rx recs…
@VPrasadMDMPH 5 yrs after reporting that a heavily promoted NGS service was reporting drug target associations as rx recs with low level evidence...seems there is still a lot of room for improvement https://t.co/2bdIM1s1Tx
Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @DrGlenWeiss et al. OncoTargets and Therapy https://t.co/Ipxd3VVyk2 #PrecisionMedicine
Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @DrGlenWeiss et al. OncoTargets and Therapy https://t.co/Ipxd3VVyk2 #PrecisionMedicine
RT @mtmdphd: Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decis…
Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making [2015] @DrGlenWeiss et al. OncoTargets and Therapy https://t.co/vgPJ9VhSVH #PrecisionMedicine #CDSupport #camoldx
@EricBernicker We reported in 2015 comparison of tumor tissue TAT out of concern of long delay and also liberal calling of “actionability”. https://t.co/KHPDvnhR2g @JackWestMD
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
It's very important to cancer treatment,we look forward to seeing some new improvement https://t.co/cCPyyOu8vW
Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making [2015] @DrGlenWeiss et al. OncoTargets and Therapy https://t.co/vgPJ9VhSVH #PrecisionMedicine #CDSupport #camoldx
Test em all on every platform and let god sort em out. Or something like that. https://t.co/PJOuJfeu8I
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
33% concordance between 2 commercial NGS platforms @JAMAOnc?! #PrecisionMedicine gets an F- in highschool. So much more work to do @Roche @CMSinnovates @ASCO https://t.co/T2BRv7nNHK
RT @arropT: Imprecision Medicine...it's time to calculate kappa index https://t.co/pykKfcjM3n
RT @arropT: Imprecision Medicine...it's time to calculate kappa index https://t.co/pykKfcjM3n
RT @arropT: Imprecision Medicine...it's time to calculate kappa index https://t.co/pykKfcjM3n
RT @VinayPrasad82: Another gem of a paper on concordance (or lack there of) of 2 commercial panels. If different panels find different gene…
NGS really needs to do better than this for #precisionmedicine to be realised. https://t.co/wFv3T3tOyk
RT @arropT: Imprecision Medicine...it's time to calculate kappa index https://t.co/pykKfcjM3n
Imprecision Medicine...it's time to calculate kappa index https://t.co/pykKfcjM3n
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
RT @DrGlenWeiss: Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3…
Concordance between F1CDx and PCDX tumor tissue NGS. All genes 4.5% concordance, while genes shared on both platforms 33.3% concordance @VinayPrasad82 @CMSGov @VivekKhemkaMD @mtmdphd https://t.co/kMKwHq0IgY https://t.co/btBY32pBPJ
You can also read about concordance between 2 tumor tissue NGS assays. https://t.co/0oWyZfqS7W **It has a wonderful letter to editor and reply**😉 https://t.co/rhWudF22Iy https://t.co/hw0mirj7le
RT @DrGlenWeiss: @EnriqueSoto8 @VinayPrasad82 @PatelOncology @oncology_bg @JackWestMD There’s also the problem of non-uniformity of “interp…
RT @DrGlenWeiss: @EnriqueSoto8 @VinayPrasad82 @PatelOncology @oncology_bg @JackWestMD There’s also the problem of non-uniformity of “interp…
@EnriqueSoto8 @VinayPrasad82 @PatelOncology @oncology_bg @JackWestMD There’s also the problem of non-uniformity of “interpretation” and “reporting” of “actionable” findings between platforms. Misleading and fanciful recs from case report or in vitro touted
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
@Aiims1742 @FoundationATCG @GuardantHealth Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
RT @mtmdphd: Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSu…
RT @mtmdphd: Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSu…
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
RT @DrGlenWeiss: Nice perspective. Can add this reference with #8 @mtmdphd https://t.co/1bRryfrQFo https://t.co/JZT0KvkJVW
RT @DrGlenWeiss: Nice perspective. Can add this reference with #8 @mtmdphd https://t.co/1bRryfrQFo https://t.co/JZT0KvkJVW
Nice perspective. Can add this reference with #8 @mtmdphd https://t.co/1bRryfrQFo https://t.co/JZT0KvkJVW
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
Here's another comparison of NGS platforms https://t.co/0oWyZfqS7W @VivekKhemkaMD https://t.co/vjfygHk38z
RT @mtmdphd: Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSu…
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
RT @mtmdphd: Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSu…
Saving this to read later. Very much interested in genomic testing progress in cancer. https://t.co/0KCekfY3as
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
RT @mtmdphd: Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSu…
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
RT @mtmdphd: Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSu…
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
some commercial NGS platforms are misleading customers w/exceedingly high rates of “actionable targets” https://t.co/5e3RVdjKzn @JNCI_Now
RT @mtmdphd: Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSu…
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/vgPJ9VhSVH #CDSupport #camoldx
RT @mtmdphd: Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss et al https://t.co/aXoJTndtlA #CDS…
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss et al https://t.co/aXoJTndtlA #CDSupport
Eval & comp 2 avail targeted NGS platforms to assist oncology decision making. @DrGlenWeiss etal https://t.co/W3JizXhoMG #CDSupport #camoldx
RT @DaleYuzuki: Comparison of 2 commercially available targeted NGS platforms to assist oncology decision making | PubMed http://t.co/1Q4co…
RT @DaleYuzuki: Comparison of 2 commercially available targeted NGS platforms to assist oncology decision making | PubMed http://t.co/1Q4co…
RT @DaleYuzuki: Comparison of 2 commercially available targeted NGS platforms to assist oncology decision making | PubMed http://t.co/1Q4co…
Comparison of 2 commercially available targeted NGS platforms to assist oncology decision making | PubMed http://t.co/1Q4conPlcA @iontorrent